Press Room

AAPS 2019

Start
Sunday, November 03, 2019 - 09:00
End
Wednesday, November 06, 2019 - 09:00
Location: Texas, United States
Booth Number: 447
Spray Drying Development by Design | Hovione

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

HOVIONE POSTERS

Poster Name / Presentation Poster Number Presenter Presentation
Date / Time
Production of Lysozyme-PLGA Particles for Extended
Release Using Hot Melt Extrusion Technology
M1230-02-09 João Henriques Nov 4
12.30 pm - 1.30 pm
A Fundamental Study on Strain Rate Sensitivity of
Spray Dried Solid Dispersions
M1330-04-23 João Henriques Nov 4
1.30 pm - 2.30 pm
Statistical Approach on the Key Parameters of a
Dosator-Based Capsule Filling Process of
Carrier-Based and Spray-Dried Powders –
Impact on the In-Vitro Aerodynamic Performance
M1430-08-50 Eunice Costa Nov 4
2.30 pm - 3.30 pm
Leveraging Amorphous Solid Dispersion Development
in an Integrated API to Tablet Pipeline
T1130-04-24 João Henriques Nov 5
11.30 am - 12.30 am
Exploring the Physical Stability of Amorphous Drugs
The Thermodynamic Toolbox
T1130-06-42 Maria Paisana Nov 5
11.30 am - 12.30 am
A Novel Laser Diffraction Methodology for the
Characterization
of ASD Speciation Events - An Itraconazole:
HPMC AS Case Study
M1230-03-17 Maria Paisana Nov 5
2.30 pm - 3.30 pm
Performance Evaluation of ASD-Based Tablets:
Can Colloid Formation be Modelled?
W0930-06-41 João Henriques Nov 6
9.30 am - 10.30 am
Comparative Evaluation of Pharmaceutical Powders
Flow Using Different Analytical Methodologies
W0930-06-42 Maria Paisana Nov 6
9.30 am - 10.30 am
Powerful Combination between AQbD
and High-Throughput Analytical Toolkit
to Support an Efficient RP-LC Method Development
W1130-06-41 Maria Paisana Nov 6
11.30 am - 12.30 am

 

You might be also interested in

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024